TerminatedNCT00044083
Clinical Trial of Tolcapone for Cognition in Schizophrenia
Medication studyAges 18–50United States
Understand this study
Who could participate?
Listed age limits: 18 years to 50 years.
- Listed locations
- BethesdaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateAugust 2002
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 210
- Sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT00044083
- Official title
Show the full official title
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
Recruitment & locations
TerminatedBethesda
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Mental Health (NIMH), a government agency.
Does this study involve medication?
Yes. The study involves medication, including Tolcapone.
Who can participate?
Listed age limits: 18 years to 50 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)